Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
Epithalon (Injectable Form)
Epitalon Injectable, AEDG Injectable
The injectable subcutaneous form of the Epithalon tetrapeptide, offering higher bioavailability than oral or nasal routes. Same active sequence (Ala-Glu-Asp-Gly) as oral Epitalon but delivered via injection for more reliable absorption. Studied for telomerase activation, pineal gland function, and circadian rhythm regulation.
A synthetic tripeptide (Glu-Asp-Arg) developed by the St. Petersburg Institute of Bioregulation and Gerontology — the same institution behind Epitalon. Pinealon is designed to target the central nervous system and pineal gland, with research focused on neuroprotection, cognitive function, and circadian rhythm regulation.
Same mechanism as oral Epitalon — stimulates telomerase activity in somatic cells, potentially slowing telomere shortening. Also modulates pineal gland melatonin production and may influence circadian rhythm regulation. The injectable route bypasses GI degradation, providing more consistent peptide delivery to target tissues.
Penetrates the blood-brain barrier and accumulates in neurons. Modulates gene expression related to neuronal survival and function. Reduces oxidative stress in neural tissue. Appears to regulate melatonin synthesis through pineal gland activity, supporting circadian rhythm normalization.
- Anti-aging and longevity protocols
- Telomere maintenance (investigational)
- Sleep quality improvement
- Circadian rhythm regulation
- Pineal gland support
- Cognitive enhancement and memory
- Neuroprotection
- Sleep quality improvement
- Age-related cognitive decline
- Stroke recovery support (preliminary research)
- Injection site reactions
- Drowsiness (melatonin-related)
- Limited human clinical data
- Long-term safety unknown
- Theoretical cancer risk from telomerase activation (unproven)
- Very limited independent Western research
- Most studies from Russian institutions
- Long-term safety unknown
- Mechanism not fully characterized
- Injection site reactions
Shares regulatory status with Epitalon. Removed from Category 2 on April 22, 2026. Scheduled for PCAC Day 2 review on July 24, 2026. Not FDA-approved for any indication.
PCAC: 2026-07-24
Not FDA-approved and not on any compounding list. Available as a research chemical. Research base is almost entirely from Russian institutions — independent replication is limited. Not affected by the 2026 regulatory changes.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.